PMID- 24272276
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20211021
IS  - 1573-2630 (Electronic)
IS  - 0165-5701 (Linking)
VI  - 34
IP  - 4
DP  - 2014 Aug
TI  - Reduced effect of anti-vascular endothelial growth factor agents on diabetics 
      with vitreomacular interface abnormalities.
PG  - 817-23
LID - 10.1007/s10792-013-9884-6 [doi]
AB  - This study investigated whether the presence of vitreomacular interface 
      abnormalities (VMIAs) affects the improvement in visual acuity and edema of 
      patients with diabetic macular edema (DME) who received three anti-vascular 
      endothelial growth factor (VEGF) injections. Fifteen eyes of 11 patients with 
      clinically significant macular edema were retrospectively divided into either the 
      control group (only DME) or the experimental group (DME and VMIA) based on 
      optical coherence tomography images. We defined VMIA patterns as epiretinal 
      membrane and/or anomalous vitreomacular adhesion. Changes in central macular 
      thickness (CMT), total macular volume (TMV), and best-corrected visual acuity 
      (BCVA) from the baseline to post third injection were compared between the two 
      groups. After the third injection, the decreases in CMT and TMV were not 
      statistically different between the two groups. The improvement in BCVA was 
      larger in the control group (0.1742 +/- 0.0508 logMAR) than in the experimental 
      group (0.0766 +/- 0.0562 logMAR; p < 0.01). Our study showed that after the third 
      anti-VEGF injection, the BCVA of patients with both DME and VMIAs improved 
      significantly less than that of patients with only DME. Our results suggest that 
      VMIAs may play a crucial role in reducing the therapeutic effects of anti-VEGF 
      agents.
FAU - Yoon, Dan
AU  - Yoon D
AD  - Department of Ophthalmology, New York University School of Medicine, 462 First 
      Ave. NBV 5N18, New York, NY, 10016, USA, dy448@nyumc.org.
FAU - Rusu, Irene
AU  - Rusu I
FAU - Barbazetto, Irene
AU  - Barbazetto I
LA  - eng
PT  - Journal Article
DEP - 20131122
PL  - Netherlands
TA  - Int Ophthalmol
JT  - International ophthalmology
JID - 7904294
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Bevacizumab
MH  - Case-Control Studies
MH  - Diabetic Retinopathy/*drug therapy
MH  - Epiretinal Membrane/*drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Macular Edema/complications/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab
MH  - Retrospective Studies
MH  - Tissue Adhesions/drug therapy/physiopathology
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/physiology
EDAT- 2013/11/26 06:00
MHDA- 2015/02/13 06:00
CRDT- 2013/11/26 06:00
PHST- 2013/09/30 00:00 [received]
PHST- 2013/11/13 00:00 [accepted]
PHST- 2013/11/26 06:00 [entrez]
PHST- 2013/11/26 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
AID - 10.1007/s10792-013-9884-6 [doi]
PST - ppublish
SO  - Int Ophthalmol. 2014 Aug;34(4):817-23. doi: 10.1007/s10792-013-9884-6. Epub 2013 
      Nov 22.